<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=euc-jp" />
<meta http-equiv="content-style-type" content="text/css" />
<meta http-equiv="content-script-type" content="text/javascript" />

<title>Epogin Injection :  Submission of an opinion letter on the application for approval of an additional indication for &quot;Epogin Injection&quot; [generic name: epoetin beta (genetic recombination)] | YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot;</title>

<meta name="Description" content="YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot;" />
<meta name="Keywords" content="YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot;" />
<meta http-equiv="imagetoolbar" content="no" />
<link rel="stylesheet" type="text/css" media="all" href="../../css/style.css" />
<link rel="stylesheet" type="text/css" media="all" href="../../css/en.css" />
<script type="text/javascript" src="../../js/jquery.js"></script>
<script type="text/javascript" src="../../js/jquery.function.js"></script>
</head>

<body class="page">
<div id="container">

<div id="header">
<p id="siteLogo"><a href="../../en.html"><img src="../../img/common/logo_en.gif" alt="YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot;" width="437" height="28" /></a></p>
<p id="tagline"> YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot; is the private medical supply supervisory system.</p>
<div id="navUtility">
<ul>
<li><a href="../sitemap.html">Sitemap</a></li>
<li><a href="../../index.html">Japanese</a></li>
</ul>
<!-- /#navUtility --></div>
<div id="searchArea">
<form name="form1" action="http://www.yakugai.gr.jp/en/search.php" method="post">
<p><input id="searchInput" name="keyword" type="text" />&nbsp;<input value="Search" type="submit" /></p>
</form>
<!-- /#searchInput --></div>
<!-- /#header --></div>

<div id="nav">
<ul>
<li id="navHome"><a href="../../en.html">Home</a></li>
<li><a href="../about.html">About Us</a></li>
<li class="current"><a href="../activity.html">Activities</a></li>
<li><a href="../inve.html">Past Issues</a></li>
<li><a href="../about/about_links.html">Links</a></li>
</ul>
<!-- /#nav --></div>

<div class="activity" id="pageTitle">
<h1>Activities</h1>
<!-- /#pageTitle --></div>

<div id="topicPath">
<ol>
<li id="topicPathHome"><a href="../../en.html">Home</a></li>
<li>Activities</li>
</ol>
<!-- /#topicPath --></div>

<div id="contents">

<div id="main">

<div class="articleHead group">
<h2>Epogin Injection :  Submission of an opinion letter on the application for approval of an additional indication for &quot;Epogin Injection&quot; [generic name: epoetin beta (genetic recombination)]</h2>
<p>2011-07-26</p>
<!-- /.articleHead -->
</div>

<p>
On July 26th 2011, we submitted an opinion letter on the application for approval of an additional indication for the &quot;Epogin Injection&quot;.<br /><br />Regarding the recombinant human erythropoietin  &quot;Epogin Injection&quot;  (hereafter referred to as &quot;the agent&quot;), Chugai Pharmaceutical Co., Ltd filed an application on November 19th 2009 for the approval of an additional indication of &quot;chemotherapy-induced anemia in solid tumour patients who are not eligible for curative surgery.&quot;  The agent has already been approved as a treatment for renal anemia experienced by patients undergoing dialysis.<br /><br />In response to this, on May 30th 2011 the Pharmaceutical and Medical Devices Agency (PMDA) concluded that EPOGIN should not be approved because the policies in place for appropriate safety management (which would avoid the risk of a worsened prognosis and promotion of cancer cell growth) are unclear, and at this stage there is no way of telling whether the benefits outweigh the risks.<br /><br />On June 23rd 2011, the Evaluation and Licensing Division of the Ministry of Health, Labor and Welfare's Pharmaceutical and Food Safety Bureau started to gather public opinions on this matter.  We also submitted an opinions letter.  <br /><br />Like the PMDA, we believe that the additional indication should not be approved, as the effects on and safety towards chemotherapy-induced anemia in solid tumour patients who are not eligible for curative surgery are yet to be established.  <br /><br />The agent is a supporting treatment for patients undergoing chemotherapy.  Chemotherapy aims to prolong patients' lives and inhibit cancer cell growth.  Under no circumstances must this fail following use of the agent.  <br /><br />However, there is also evidence that patients face an extremely high risk of developing blood clots or cancer tumours, both of which can shorten life expectancy.  Furthermore, there is currently no method in place that mitigates these risks appropriately.<br /><br />Concerning its effects, the applicant has explained that the agent increases the quality of life (QOL) of those taking it, but there is no data from clinical studies with this as a primary endpoint.  In addition, there are doubts towards the benchmark used by the applicant to judge the agent's effects (blood transfusion rate) and how this and other criteria were decided upon.<br /><br />Therefore, in view of the fact that patients undergoing chemotherapy can receive other forms of treatment (red blood cell transfusion), we believe the agent cannot be approved at this stage, in line with the PMDA's results.  <br />
</p>
<div id="articleData">
<dl>
<dt>Related Documents And URL</dt>
<dd>
<ul>
<ul class="basis">
<li> <a href="../../topics/file/en/opinion_letter_on_epogin_injection_2011_July_26.pdf" target="_blank">An opinion letter on Epogin Injection (Japanese)</a>（170 KB）</li></ul>

</ul>
</dd>
</dl>
<!-- /#articleData -->
</div>
<!-- /#main --></div>

<div id="sub">
<h2>Table Of Contents</h2>
<div id="navSub">
<ul>
<li><a href="../activity/index.php@year=2019.html">2019</a></li>
<li><a href="../activity/index.php@year=2018.html">2018</a></li>
<li><a href="../activity/index.php@year=2017.html">2017</a></li>
<li><a href="../activity/index.php@year=2016.html">2016</a></li>
<li><a href="../activity/index.php@year=2015.html">2015</a></li>
<li><a href="../activity/index.php@year=2014.html">2014</a></li>
<li><a href="../activity/index.php@year=2013.html">2013</a></li>
<li><a href="../activity/index.php@year=2012.html">2012</a></li>
<li><a href="../activity/index.php@year=2011.html">2011</a></li>
<li><a href="../activity/index.php@year=2010.html">2010</a></li>
<li><a href="../activity/index.php@year=2009.html">2009</a></li>
<li><a href="../activity/index.php@year=2008.html">2008</a></li>
<li><a href="../activity/index.php@year=2007.html">2007</a></li>
<li><a href="../activity/index.php@year=2006.html">2006</a></li>
<li><a href="../activity/index.php@year=2005.html">2005</a></li>
<li><a href="../activity/index.php@year=2004.html">2004</a></li>
<li><a href="../activity/index.php@year=2003.html">2003</a></li>
<li><a href="../activity/index.php@year=2002.html">2002</a></li>
<li><a href="../activity/index.php@year=2001.html">2001</a></li>
<li><a href="../activity/index.php@year=2000.html">2000</a></li>
<li><a href="../activity/index.php@year=1999.html">1999</a></li>
<li><a href="../activity/index.php@year=1998.html">1998</a></li>
<li><a href="../activity/index.php@year=1997.html">1997</a></li>

</ul>
<p><a href="../activity/event.php.html">Event list</a></p>
<!-- /#navSub --></div>
<!-- /#sub -->
</div>
<!-- /#contents --></div>

<div id="footer">
<p id="siteAdress">YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot; Tie-up group<br />
160-0022　Tokyo Shinjuku Ward Shinjuku 1-14-4  AM building<br />
TEL : 03（3350）0607　FAX : 03（5363）7080<br />
Mail : <a href="mailto:info@yakugai.gr.jp">&#105;&#110;&#102;o&#64;y&#97;&#107;u&#103;&#97;&#105;&#46;&#103;r.&#106;&#112;</a></p>

<div id="footerInner">
<ul id="navFooter">
<li><a href="../privacy.html">Privacy Policy</a></li>
</ul>
<p id="siteInfo">Our members have other regular jobs and volunteer their services free of charge. Our secretariat also serves as part-time basis, and we are currently in the process of facilitating the secretariat function. Therefore, please note that due to limited resources, we might not be able to respond to each inquiry on specific medicine. Thank you for your understanding.</p>
<p id="copyright"><img src="../../img/common/copyright.gif" alt="Copyright (c) YAKUGAI Ombudsperson &quot;Medwatcher Japan&quot;. all rights reserved." width="419" height="11" /></p>
<!-- /#footerInner --></div>

<!-- /#footer --></div>

<!-- /#container --></div>

<!-- google Analytics -->
<script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
<script type="text/javascript">
try {
var pageTracker = _gat._getTracker("UA-11615542-1");
pageTracker._trackPageview();
} catch(err) {}
</script>
<!-- /google Analytics -->
<!-- nakanohito -->
<script LANGUAGE="Javascript">
<!--
var refer = document.referrer;
document.write("<a href='http://nakanohito.jp/'>");
document.write("<img src='http://nakanohito.jp/an/?u=202528&h=897479&w=48&guid=ON&t=&version=js&refer="+escape(parent.document.referrer)+"&url="+escape(parent.document.URL)+"' border='0' width='48' height='48' />");
document.write("</a>");
//-->
</script>
<noscript>
<img src="http://nakanohito.jp/an/?u=202528&h=897479&w=48&guid=ON&t=" width="48" height="48" alt="" border="0" />
</noscript>
<!-- nakanohito end -->

</body>
</html>